Get the Stockscreener App
0.5842
5.41%
-0.0334
Aprea Therapeutics Inc stock is traded at $0.5842, with a volume of 159.85K.
It is down -5.41% in the last 24 hours and down -20.03% over the past month.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
See More
Previous Close:
$0.6176
Open:
$0.658
24h Volume:
159.85K
Relative Volume:
0.99
Market Cap:
$7.36M
Revenue:
$123.30K
Net Income/Loss:
$-11.95M
P/E Ratio:
-0.3788
EPS:
-1.5421
Net Cash Flow:
$-12.57M
1W Performance:
-3.34%
1M Performance:
-20.03%
6M Performance:
-35.64%
1Y Performance:
-62.06%
1-Day Range:
$0.5729
$0.658
1-Week Range:
$0.5729
$0.658
52-Week Range:
$0.548
$1.69
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.5842 | 7.36M | 123.30K | -11.95M | -12.57M | -1.5421 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-26 | Initiated | Ladenburg Thalmann | Buy |
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Aprea Therapeutics to Present at October Conferences - The Manila Times
Aprea Therapeutics, Inc. (APRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aprea Puts Cancer Drug Pipeline Before Investors - MyChesCo
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials - Clinical Leader
Aprea Therapeutics Inc (APRE:UR): Stock Price, Quote and News - bnnbloomberg.ca
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Expands Patent Portfolio for Precision Oncology Programs - minichart.com.sg
Aprea Therapeutics reports patent portfolio of 58 patents - Investing.com
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com Canada
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com India
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - manilatimes.net
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com UK
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - Barchart.com
Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ) - Seeking Alpha
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Expansion Phase - vinanet.vn
Aprea (APRE) Stock: Advances 1.19% to $0.64 in the Latest Reading; Market Levels: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateHigh Volume Node - vinanet.vn
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateOne-Time Loss Impact - careplusvn.com
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Weakness Phase - dars.gov.et
Aprea (APRE) Q1 2026 Scorecard: EPS Exceeds Its Estimate in the Latest Session; Stock Move: The Market Price Declines 2.61% at the CloseInterim Report - careplusvn.com
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotChandelier Stop - vinanet.vn
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotLow Risk Entry Stocks - dars.gov.et
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined ExecutionEarnings Recovery Stocks - Vinanet
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity - MyChesCo
Aprea Therapeutics (APRE) Edges Higher by 1.34% as Shares Hover Above Key SupportStrangle Setup - vinanet.vn
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Mid Cap Momentum - vinanet.vn
Oppenheimer Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Quote Data - dars.gov.et
Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
APRE: APR-1051 demonstrates promising early efficacy and safety, driving a biomarker-focused oncology pipeline - TradingView
Aprea Therapeutics advances APR-1051 oncology pipeline progress - TipRanks
Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India
Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan
Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative
Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - finance.yahoo.com
Price to earnings forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView
Aprea Therapeutics Inc (APRE) Stock News Today - TradingKey
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aprea Expands APR-1051 Trial as Enrollment Accelerates - mychesco.com
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aprea Therapeutics Inc Stock (APRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Jan 30 '26 |
Buy |
0.89 |
5,700 |
5,073 |
33,433 |
| Duey Marc | Director |
Dec 10 '25 |
Buy |
1.17 |
21,459 |
25,000 |
256,155 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):